{"id":11363,"date":"2023-11-20T11:33:00","date_gmt":"2023-11-20T03:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11363"},"modified":"2024-11-05T11:38:17","modified_gmt":"2024-11-05T03:38:17","slug":"wuxi-biologics-subsidiary-wuxi-xdc-lists-on-hong-kong-stock-exchange","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11363","title":{"rendered":"WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange"},"content":{"rendered":"\n

WuXi Biologics (HKG: 2269<\/a>) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268<\/a>) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds are estimated to be around HKD 4 billion (USD 510 million), assuming full exercise of an over-allotment of 19.1 million shares.<\/p>\n\n\n\n

Expanding WuXi XDC’s Global CDMO Capabilities<\/strong>
The funds raised by WuXi XDC will be directed towards expanding its capabilities and capacity as a contract development and manufacturing organization (CDMO) on a global scale. This expansion includes facility construction in Singapore, increased manufacturing capacity in China, and the pursuit of partnerships and investment\/acquisition opportunities.<\/p>\n\n\n\n

WuXi XDC’s Comprehensive Services in Bioconjugation and ADC Development<\/strong>
WuXi XDC specializes in end-to-end services from discovery to commercial production, with a focus on bioconjugation and particularly antibody drug conjugate (ADC) development. The company offers a range of services including antibody and other biologic intermediates, chemical payloads and linkers, and bioconjugate drug substances. Both clinical and commercial stage production are within WuXi XDC’s scope of services. According to the press release, WuXi XDC can significantly shorten the ADC development timeline to just 13-15 months from antibody DNA sequence to Investigational New Drug (IND) filing, which is approximately a 50% reduction from the industry average.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,19,20,1183,952,72,292,364],"class_list":["post-11363","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-cro-cmo-cdmo","tag-finance","tag-hkg-2268","tag-hkg-2269","tag-ipo","tag-wuxi-biologics","tag-wuxi-xdc"],"yoast_head":"\nWuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds are estimated to be around HKD 4 billion (USD 510 million), assuming full exercise of an over-allotment of 19.1 million shares.WuXi Biologics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11363\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11363\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-20T03:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T03:38:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange\",\"datePublished\":\"2023-11-20T03:33:00+00:00\",\"dateModified\":\"2024-11-05T03:38:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"HKG: 2268\",\"HKG: 2269\",\"IPO\",\"WuXi Biologics\",\"WuXi XDC\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11363#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11363\",\"name\":\"WuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-20T03:33:00+00:00\",\"dateModified\":\"2024-11-05T03:38:17+00:00\",\"description\":\"WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds are estimated to be around HKD 4 billion (USD 510 million), assuming full exercise of an over-allotment of 19.1 million shares.WuXi Biologics\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11363\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11363#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","description":"WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds are estimated to be around HKD 4 billion (USD 510 million), assuming full exercise of an over-allotment of 19.1 million shares.WuXi Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11363","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11363","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-20T03:33:00+00:00","article_modified_time":"2024-11-05T03:38:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11363#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11363"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange","datePublished":"2023-11-20T03:33:00+00:00","dateModified":"2024-11-05T03:38:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11363"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","CRO \/ CMO \/ CDMO","Finance","HKG: 2268","HKG: 2269","IPO","WuXi Biologics","WuXi XDC"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11363#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11363","url":"https:\/\/flcube.com\/?p=11363","name":"WuXi Biologics' Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-20T03:33:00+00:00","dateModified":"2024-11-05T03:38:17+00:00","description":"WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds are estimated to be around HKD 4 billion (USD 510 million), assuming full exercise of an over-allotment of 19.1 million shares.WuXi Biologics","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11363#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11363"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11363#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11363"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11363\/revisions"}],"predecessor-version":[{"id":11364,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11363\/revisions\/11364"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}